Prevention of Chronic Headache in Patients Diagnosed With Idiopathic Intracranial Hypertension With a Monoclonal Anti-calcitonin Gene-related Peptide Antibody: A Double-blinded Randomized Placebo-controlled Multicentre Trial

The goal of this clinical trial is to learn if eptinezumab can reduce headache frequency and headache-related disability in adults with idiopathic intracranial hypertension (IIH) and chronic headache. It will also evaluate the safety and tolerability of eptinezumab in this patient population.

The main questions it aims to answer are:

• Does eptinezumab reduce the number of monthly moderate-to-severe headache days compared with placebo?
• Does eptinezumab improve headache-related disability and patient-reported outcomes?
• What adverse events occur during treatment with eptinezumab?

Researchers will compare eptinezumab to placebo to determine whether eptinezumab is effective in the prevention of chronic headache in patients with IIH.

Participants will:

• Receive eptinezumab or placebo according to random assignment.
• Attend scheduled study visits and clinical assessments.
• Complete headache diaries and questionnaires during the study period.
• Undergo study-related examinations and collection of biological samples, including blood samples.